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ABSTRACT 
 
Copy number variations (CNV) are important in the aetiology of neurodevelopmental 
disorders and show broad phenotypic manifestations. We compared the presence of small 
CNVs disrupting the ELP4-PAX6 locus in 4,092 U.K. individuals with a range of 
neurodevelopmental conditions, clinically referred for array comparative genomic 
hybridisation (aCGH), with WTCCC controls (n=4,783). The phenotypic analysis was then 
extended using the DECIPHER database. We followed up association using an autism patient 
cohort (n=3,143) compared with six additional control groups (n=6,469). In the clinical 
discovery series we identified eight cases with ELP4 deletions, and one with a partial 
duplication of ELP4 and PAX6. These cases were referred for neurological phenotypes 
including language impairment, developmental delay, autism and epilepsy. Six further cases 
with a primary diagnosis of ASD and similar secondary phenotypes were identified with 
ELP4 deletions, as well as another six (out of 9) with neurodevelopmental phenotypes from 
DECIPHER. CNVs at ELP4 were only present in 1/11,252 controls. We found a significant 
excess of CNVs in discovery cases compared with controls, p=7.5x10
-3
; as well as for autism, 
p=2.7x10
-3
. Our results suggest ELP4 deletions are highly likely to be pathogenic, 
predisposing to a range of neurodevelopmental phenotypes from ASD to language 
impairment and epilepsy. 
 
Key Words: Copy Number Variation (CNV), Epilepsy and seizures, Developmental, 
Neurology 
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INTRODUCTION 
 
Copy number variation (CNV) plays an important role in the aetiology of neurodevelopmental 
and psychiatric disorders. Both recurrent de novo and rare segregating CNVs have begun to 
explain the overlap of diverse phenotypes in individual cases and families (Cooper, et al., 
2011; Malhotra and Sebat, 2012). Copy number variation is a strong risk factor in both focal 
and generalized epilepsies, and they are also found in 8% of patients with epileptic 
encephalopathies (Mefford, et al., 2010; Mefford, et al., 2011). Recent findings in the rare 
epileptic encephalopathies illustrate the connection between epilepsy, language impairment 
and autism spectrum disorder (ASD) through overrepresentation of novel CNVs containing 
cell adhesion genes, (e.g. cadherins and contactins) (Lesca, et al., 2012). However, there are 
also differences between disorders: for example, specific language impairment cases, whilst 
having an increased burden of CNVs, do not in general show enrichment for novel or de novo 
events (Simpson, et al., 2015), whereas rare copy number variation is an important source of 
risk in ASD (Pinto, et al., 2014).  
 
The examples above indicate that a given genomic alteration can sustain broad susceptibility 
to several phenotypes depending on the genetic background of the subject. So called ‘hotspot’ 
CNVs also manifest this phenotypic variability. The recurrent 15q13.3 microduplication 
increases the risk for intellectual disability, idiopathic generalised epilepsy, ASD and 
schizophrenia and (Helbig, et al., 2009; Poot, et al., 2011), and deletions at 16p13.11 
contribute to a diverse spectrum of epilepsy disorders (Heinzen, et al., 2010). The 16p11.2 
hotspot is also pleiotropic; deletions are common in ASD and developmental delay, 
(Marshall, et al., 2008) and duplications have been associated with seizures and speech delay 
(Shinawi, et al., 2010).  Other notable examples of pleiotropy are CNVs of the CNTNAP2 
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gene, which are implicated in ASD, Gilles de la Tourette syndrome, schizophrenia and 
epilepsy, and AUTS2 with ASD and mental retardation. Interestingly AUTS2 and CNTNAP2 
may interact with each other on a molecular level, (Poot, et al., 2011), indicating emerging 
convergent pathways for neurodevelopment. A recent report of a deletion of the ELP4 gene at 
11p13, and adjacent 3’ PAX6 enhancer elements has been described in a case with aniridia, 
autism and mental retardation. This case differs from the ‘classical’ PAX6 gene deletions 
causing aniridia alone, as only the 3’ enhancer elements are deleted in this case and ELP4 is 
included (Davis, et al., 2008). ELP4 has previously been associated with the 
electroencephalographic (EEG) signature of the common childhood epilepsy Rolandic 
epilepsy (RE) (Strug, et al., 2009), and such EEG abnormalities as well as epilepsy are well 
established in autism spectrum disorder (ASD) and language impairments, (Nasr, et al., 2001; 
Parmeggiani, et al., 2010).  These examples illustrate again that genomic alterations can show 
broad phenotypic manifestations during neurodevelopment, as well as incomplete penetrance. 
 
In the present study we report the presence of a number of deletions of ELP4 and the 
regulatory elements of PAX6 in the U.K. database of individuals with a childhood onset 
developmental condition referred for clinical genetic testing (BB-GRE). We test the 
hypothesis that the burden of ELP4 CNVs is increased in those with neurodevelopmental 
conditions compared to controls. This phenotypic analysis is then extended using the 
DECIPHER database of chromosomal imbalances in over 10,000 cases of developmental 
disorders. Using a CNV-led approach we then further expand the phenotype associated with 
ELP4 microdeletions to cases with ASD and varying comorbidities, and carry out a second 
case-control analysis of frequency. This data supports our hypothesis that disruption of ELP4 
and the regulatory regions of PAX6 contained within its introns, lead to a range of 
neurodevelopmental conditions.
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METHODS 
 
Study Design 
We used a three-stage design; first testing the hypothesis of CNV enrichment at ELP4 in a 
clinical discovery sample of developmental disorders (Brain and Body Genetics Research 
Exchange (BBGRE, https://bbgre.iop.kcl.ac.uk) and control dataset (WTCCC), both from the 
U.K.; second, extending the phenotypic analysis to a larger dataset of developmental 
disorders (DECIPHER) and finally, replicating the association to neurodevelopmental 
disorders in ASD cases (Autism Genome Project and two Canadian ASD cohorts) compared 
to a large multi-centre control sample set.  
 
Samples 
U.K. Clinical Dataset – BB-GRE 
4092 children referred to Guy's and St Thomas NHS Foundation Trust, southeastern UK from 
paediatricians and regional hospitals, https://bbgre.iop.kcl.ac.uk. Individuals referred for 
array-CGH testing for a range of developmental problems including developmental delay 
(DD), ASD, speech or language delay or congenital defects. Individuals had clinical 
diagnoses made prior to genetic testing, which was part of standard clinical care. Genomic 
data and referral phenotype information were anonymised and recorded in a clinical database, 
(63% males; August 2014). 
 
Global Clinical Dataset - DECIPHER  
We performed a search in the DECIPHER database (Firth, et al., 2009) in order to identify 
additional cases with small CNVs which included and/or disrupted ELP4. DECIPHER 
(Database of Chromosomal Imbalance and Phenotype in Humans Using Ensembl Resources, 
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http://decipher.sanger.ac.uk) is an interactive web-based database of over 10,000 cases which 
enables clinical scientists to maintain records of phenotype and chromosome rearrangement, 
to aid patient diagnosis by linking to other bioinformatics resources and interactive tools, and 
to share this information with the clinical research community. 
 
Canadian ASD Samples  
The cohort contained 349 probands previously published (Lionel, et al., 2011) and 350 
additional patients diagnosed with ASD from Canada described below, totaling 699. 
Individuals were recruited from four different Canadian sites: The Hospital for Sick Children, 
Toronto; McMaster University, Hamilton; Memorial University, St. John's, Newfoundland 
and University of Alberta, Edmonton. All had a clinical diagnosis of ASD, using the Autism 
Diagnostic Interview-Revised (ADI-R) and/or Autism Diagnostic Observation Schedule 
(ADOS).  
 
Autism Genome Project (AGP) Samples  
2,147 European ASD cases were genotyped as part of a study by the AGP Consortium for 
rare CNVs affecting autism and are formally described in the following reference, (Pinto, et 
al., 2014). All cases had a clinical diagnosis of autism rated using the ADI-R and/or the 
ADOS.  
 
Control Populations 
A total sample of 11,252 controls from six different datasets were included this study. Group 
1 was compared with the BBGRE cases, and groups 2-6 with the AGP cases: (1) WTCCC, 
Wellcome Trust Case Control Consortium controls - 4,783 population controls from the UK 
(Consortium, et al., 2010) (2) Ottawa Heart Institute (OHI) controls - A cohort of 1,234 
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control individuals collected as part of a large case control GWA study (Stewart, et al., 2009); 
(3) German POPGEN controls – a sample of 1,123 individuals of northern German origin 
(Schleswig-Holstein) (Krawczak, et al., 2006); (4) Ontario Population Genomics Platform 
(OPGP) controls – a Canadian sample of 416 control individuals of European ancestry 
(http://www.tcag.ca/facilities/cyto_population_control_DNA.html); (5) HapMap3 controls - a 
sample of 1,056 individuals from populations from around the world from the International 
HapMap Project (http://www.hapmap.org/); (6) Controls from the AGP project –consisting of 
2,640 of European ancestry assembled from three studies in which subjects had no obvious 
psychiatric history: 'Study of Addiction Genetics and Environment (SAGE)', 'Ontario 
Colorectal Cancer case-control study (OC)', and the 'Health, Aging, and Body Composition 
(HABC)’. 
 
Genotyping and CNV Analysis 
Array CGH analysis of BB-GRE Samples 
Array CGH testing was carried out at the Guys and St Thomas’ Services cytogenetics CPA 
accredited laboratory. We have previously described the protocols, analysis and interpretation 
using an Agilent oligonucleotide array 60K platform (AMAID 028469 and 017457) and a 
patient vs. patient hybridization strategy and 3-probe minimum aberration call in (Ahn, et al., 
2013; Ahn, et al., 2010). The average probe density over ELP4 is 8.5Kb, giving a limit of 
around 25Kb for detection. CNVs in this population are available by application to BB-GRE; 
https://bbgre.iop.kcl.ac.uk/. 
 
Canadian ASD and Control Groups 1-5  
Canadian ASD cases, and control populations 1-5, were genotyped using the Affymetrix 
Genome-Wide Human SNP Array 6.0 with standard protocols. Arrays meeting Affymetrix 
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quality control guidelines of Contrast QC > 0.4 were further analysed.  Raw data analysis was 
carried out using a multiple-algorithm approach to maximize sensitivity and specificity of 
CNV calling, as described previously (Lionel, et al., 2011; Silversides, et al., 2012). Briefly, 
arrays were analyzed for CNVs with Birdsuite (Korn, et al., 2008) iPattern (Pinto, et al., 
2011) and Affymetrix Genotyping Console and merged into a single dataset. A CNV call was 
considered high confidence if it was detected by at least two of the calling algorithms and 
spanned at least 10kb and >5 consecutive array probes. Average probe density over ELP4 was 
2.0Kb, giving a limit of around 10Kb for detection. 
 
Autism Genome Project Samples and Control Group 6 
2,147 ASD cases and 2,640 controls were genotyped with the Illumina Infinium 1M SNP 
microarray. CNV calling was performed using a multi-algorithm approach incorporating 
PennCNV, iPattern and QuantiSNP (Pinto, et al., 2010). Subsequent analyses focused on 
those CNVs spanning five or more array probes and detected by at least two algorithms. The 
analysis is formally described in (Pinto, et al., 2014). The average probe density over ELP4 
was 2.1Kb, giving a limit of around 10Kb for detection. 
 
Association analysis 
A two-tailed Fishers exact test was used to compare frequencies of ELP4 CNVs in the 4,092 
cases in BB-GRE with the 4,783 controls from the WTCCC. Subsequently another two-tailed 
Fishers exact test was used to compare the frequency in 2,845 unrelated ASD cases compared 
to 6,469 controls from control sets 2-6 combined. 
 
Limitations 
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A limitation of this study is that the CNVs were not identified on the same platform or by the 
same analysis method between the sample sets. Therefore there is a chance of false CNV 
enrichment related to probe density, data quality and analysis methods. However, all 
platforms are high-density, with probe coverage shown in Figure 1. This ensures ELP4 and 
the surrounding region is well covered, and indeed the control data is generated on higher 
density platforms than the BBGRE cases, resulting in a higher CNV detection power for 
controls. We have also ensured that all reported CNVs can be called using all three 
methodologies. The Canadian ASD cases and control groups 1-5, also use the same platform 
and analysis methods as each other. Cases and controls from the AGP study also used the 
same array and analysis methods as each other. To reduce the chance of error, all of the CNV 
calling methods from each data set employ published, rigorous quality control measures as 
detailed above, ensuring that CNVs called are highly unlikely to be false positives. All of the 
ASD CNVs have also been validated by orthogonal methods such as qPCR. By also using 
data sets with different platforms, we have shown that our results are consistent even between 
the different methods used. 
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RESULTS   
 
Copy Number Variation of ELP4 in the BB-GRE Database 
Out of 4092 individuals referred for neurodevelopmental disorders, we identified nine patients 
with small (<1Mb) CNVs disrupting ELP4 that could also have be detected by the other array 
methods.  Eight CNVs were deletions, Figure 1 and Table 1, varying in size from 26Kb to 
101Kb. The ninth CNV was a 232Kb duplication of the first 7 exons of ELP4 and the PAX6 
gene. This patient also carried a ‘hotspot’ deletion of 1.2Mb at 16p13.11, which is also 
implicated in several neuropsychiatric disorders (Heinzen, et al., 2010). One deletion 
(117374) is intronic, but does however disrupt regulatory enhancers of PAX6 and so is 
included in our analysis. Four of the deletions were maternally inherited and two were 
paternally inherited, one arose de-novo and one had unknown inheritance. The inheritance 
pattern of the duplication was also unknown. Clinical information was not available for the 
parents as it is not collected for BBGRE and referring clinicians cannot be contacted. Three of 
the deletion patients carried a second CNV, Table 1, none of which are predicted to affect the 
phenotype; 119460 had a deletion of unknown inheritance of 77.6Kb at 5q21 with no genes 
present in the region, and 112601 had a maternally inherited 226Kb duplication at 5q15 
disrupting FAM172A, a potential tumor suppressor. Patient 130693 carried a maternally 
inherited duplication of 23Kb at 6p22.2, disrupting the MHC-associated genes BTN3A3 and 
BTN2A1.  
 
All cases were diagnosed with a neurodevelopmental phenotype; five had speech and 
language delay or disorder, with one also diagnosed with epilepsy, two had social 
communication difficulties and two had a diagnosis of autism, with one further case showing 
emerging autistic traits. Six of the patients also had a range of cognitive delays, Table 1. 
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Unfortunately we do not know the age at last neurological assessment for BBGRE cases; only 
age at aCGH testing is recorded. Therefore some cases may be too young for some 
phenotypes to manifest and be reported, e.g. 117003. 
 
Only one CNV involving ELP4 was found in the WTCCC control set; a 221Kb 
microdeletion, Supplementary Information Table 1. On comparison of the U.K. BB-GRE 
samples with the WTCCC controls, the difference in CNV frequency disrupting ELP4 was 
significant; p-value=7.5x10
-3
.  
 
Microdeletions of ELP4 in the DECIPHER Database 
We identified nine individuals with a small (< 1Mb) CNV encompassing ELP4 in the 
DECIPHER database (https://decipher.sanger.ac.uk) (Firth, et al., 2009). All were deletions, 
Table 2, with at least one breakpoint within the gene.  Detailed phenotypic information was 
available for eight of the nine patients; six individuals were diagnosed with developmental 
delay or intellectual disability. Several cases had speech delay; two had behavioral disorders, 
one was diagnosed with a pervasive developmental disorder (PDD), most likely ASD, and 
one further case had ASD. Another case was also diagnosed with ADHD and epilepsy 
(257614). Three cases were too young at the age of last clinical visit (263619, 265704 and 
287341) for a full assessment of neurodevelopmental phenotypes such as ASD. 
 
Two cases, 289275 and 270752, had deletions that disrupted PAX6 exons. Most likely due to 
PAX6 enhancer or exon disruption, these two cases, as well as 265704 and 263741, also have 
aniridia, an abnormality of the iris. Two others cases, 257614 and 249728, have congenital 
eye malformations but deletion breakpoints much further from PAX6. The remaining three 
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cases, whilst having breakpoints very similar to those with aniridia, do not share that 
phenotype, indicating a complex genotype-phenotype relationship.  
 
Two cases carried a second CNV: 289275 had an intronic duplication of ZNF674 at Xp11.3, 
and 261471 a 245Kb deletion at 10p11.21, disrupting CUL2, CREM and CCNY, genes not 
involved in neuronal development. 
 
Microdeletions of ELP4 in Autism Cases 
Given that several individuals from BB-GRE and DECIPHER have ASD, PDD or social 
communication difficulties, we decided to investigate the prevalence of ELP4 CNVs in two 
autism cohorts.  Out of 2,446 cases from the Autism Genome Project, AGP, (Pinto, et al., 
2014) three had microdeletions of ELP4, Table 2. All three fulfilled the criteria for a strict 
definition of autism, and were verbal (verbal IQ >70), but experienced language delay of first 
words and phrases. None of the cases had a history of seizures or epilepsy. Case 8596_201 
also carried a 500Kb maternally inherited duplication disrupting the collagen gene COL27A1 
that is highly unlikely to contribute to the neurological phenotype. 
 
Three out of 699 individuals from the Canadian autism study also carried ELP4 deletions, 
Table 3.  An affected sister pair both had a 112Kb deletion of half of the gene, and a male 
case carried a 130Kb deletion of the 3’ (but proximal due to reverse gene orientation) part of 
ELP4 and neighboring IMMP1L. Again, all three had speech and language delay and the 
sister-pair had mild developmental delay. Interestingly, the sisters also both carried a deletion 
of one copy of exon 2 of TMLHE, an enzyme involved in carnitine biosynthesis, on Xq28.  
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A case-control analysis of the frequency of ELP4 CNVs from unrelated individuals in these 
2,845 ASD cases compared with 6,469 control individuals from groups 2-6, where no ELP4 
CNVs were found, yielded a highly significant p value of 2.7x10
-3
.
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DISCUSSION 
 
In this study we have found a strong and consistent pleiotropic association between CNVs 
disrupting ELP4 and neurodevelopmental conditions over several experimental platforms. We 
have described CNVs that can be captured and called from all three high density 
platforms/methods. We have also addressed the potential problem of enrichment bias of 
CNVs in cases, as all control data is generated on higher density platforms than the BBGRE 
cases, or the same as ASD/DECIPHER cases, resulting in a higher CNV detection power for 
controls. CNVs disrupting ELP4 appear to be rare in the general population given that we 
found only one CNV in the six control groups studied (total n = 11,252), and that there are no 
regions of segmental duplication around the gene (UCSC Segmental Duplication track, 
(Bailey, et al., 2002)). ELP4 now joins the growing list of genes such as CNTNAP2, SHANK3 
and NRXN1, where heterozygous copy number are repeatedly associated with a wide range of 
neuropsychiatric disorders (Gregor, et al., 2011; Lesca, et al., 2012; Poot, et al., 2011).  
 
We have extended the phenotype associated with disruptions of ELP4 from the EEG signature 
of Rolandic epilepsy and speech sound disorder (Pal, et al., 2010; Strug, et al., 2009) to ASD, 
social communication difficulties, developmental delay, and epilepsy. This corroborates the 
findings of Davis et al, who found a deletion of ELP4 and PAX6 enhancer elements in a 
patient with autism, aniridia and mental retardation that was inherited from an affected mother 
(Davis, et al., 2008). The ELP4 locus may influence the development of language function, as 
a frequent trait across almost half of the 24 patients described here are speech and language 
difficulties. There appears to be a genetic crossroads between childhood epilepsy, autism, and 
speech and language disorders. Several genes and pathways provide a common link such as 
the cell adhesion genes cadherins and catenins, glutamate receptors GRIN2A and 2B, brain-
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expressed nuclear proteins such as AUTS2, and the transcription factor FOXP2 (Graham and 
Fisher, 2012; Lesca, et al., 2013; Lesca, et al., 2012; Poot, et al., 2011).  
 
ELP4 is one of six subunits (ELP1-6) of the Elongator complex, which plays a role in 
transcriptional elongation (Wittschieben, et al., 1999), tRNA modification and polarized 
exocytosis (Huang, et al., 2005). This complex also regulates the migration of multiple cell 
types; e.g. ELP1 co-localises with filamin A in membrane ruffles, and when depleted creates 
a disorganised actin cytoskeleton, contributing to motility defects (Johansen, et al., 2008). 
Impairment of Elongator may be involved in several different neurological disorders 
(Nguyen, et al., 2009) e.g. variants within ELP3 are associated with cases of sporadic ALS, a 
progressive motor-neuron disease (Simpson, et al., 2009).  Furthermore, mutations of ELP1 
cause familial dysautonomia (Slaugenhaupt, et al., 2001), a neurodevelopmental and 
neurodegenerative disorder with EEG abnormalities and seizures, characterized by defects in 
neironal development and survival. Elongator also underlies the migration and branching of 
cortical projection neurons during development and memory consolidation (Creppe, et al., 
2009). Thus there are several mechanisms through which disruption of ELP4 could result in 
altered neuronal development and migration, as well as the balance of neuronal excitatory and 
inhibitory circuits. These changes may disrupt Elongator function in a temporal and regional 
manner depending on cellular context and the different array of Elongator targets available.  
 
It is of note that the large intronic regions between exons 9 and 12 of ELP4 are 
ultraconserved. They contain long-range cis-regulatory enhancers for downstream PAX6, 
which are tissue- or developmental stage specific in their expression (McBride, et al., 2011). 
PAX6 is a transcription factor crucial for the correct development of the eyes, spinal cord, 
several brain regions and other organs. Deletions of PAX6 with WT1 cause Wilms tumor, 
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aniridia, genital anomalies, and intellectual disability (WAGR syndrome). Loss-of-function 
mutations in PAX6 also cause aniridia. A rare case of duplication of PAX6 and the last two 
exons/introns of ELP4 has been reported with frontotemporal neonatal seizures, 
developmental delay, microcephaly and minor ocular findings, (Aradhya, et al., 2011). 
Recently PAX6 has also been proposed as the foremost transcription factor governing 
glutamatergic neuronal differentiation (Kim, et al., 2014), linking it with the major idiopathic 
focal epilepsy gene glutamate receptor GRIN2A. Therefore disruption of PAX6 and/or its 
regulatory elements within ELP4 and its link via the glutamatergic neurotransmission system 
described above also make it a prime candidate for involvement in the neurodevelopmental 
disorders described in some cases here. However, whilst it is difficult to untangle which gene 
is causing which penotype in a few cases, for the majority, PAX6 is not disrupted, indicating 
the phenotypic consequences of ELP4 disruption alone. 
 
The genetic model of disease described here is clearly not monogenic: in 14/24 patients the 
ELP4 CNVs were inherited (13 unrelated events due to the ASD sister pair); four occurred de 
novo and six were of unknown inheritance. The phenotypic status of most parents is unknown 
and therefore a precise estimation of penetrance will require further segregation studies. 
However, presuming that the majority of the parents are unaffected, these inherited CNVs are 
unlikely to cause a phenotype by reduced expression from haploinsufficiency alone. It is most 
likely that an interacting model of disease is in action and screening of the second allele of 
ELP4 and its regulatory regions can rule out the unmasking of recessive mutations. We note 
that sequencing of ELP4 exons has failed to find mutations within RE patients (Reinthaler, et 
al., 2014) and postulate that disruption of the regulatory elements of ELP4 and/or of PAX6 
within its introns could be causal in the developmental disorders described here. 
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A two-hit hypothesis can explain CNVs that are non-syndromic, i.e. those that are associated 
with variable phenotypes and not always inherited, such as the deletions described here, 
(Girirajan and Eichler, 2010). One hit may reach a threshold to induce some sub-clinical 
features and create a sensitized background, onto which the second hit (mutation or second 
CNV) occurs producing a more severe phenotype. If we assume that these disorders share 
common neurodevelopmental pathways, the final disease outcome will then differ depending 
on the combination of genes affected. Interestingly, a sister pair with ASD in our study who 
shared the same ELP4 microdeletion, also shared a microdeletion of exon 2 of the carnitine 
biosynthesis enzyme gene TMLHE, on Xq28. Deletions of TMLHE are important in non-
dysmorphic autism in male-male multiplex families, although with low penetrance (Celestino-
Soper, et al., 2012). However the significance in females is unclear.  It is possible that 
deletion of the only copy of TMLHE is enough of a risk factor for some males to develop 
ASD, but for females (who normally have two copies of TMLHE), further ‘hits’ are 
necessary, such as the loss of ELP4 in these sisters. Several other patients also carry a second 
CNV, as described earlier, but it is unlikely that these specific CNVs contribute to the 
neurological phenotype. Exome sequencing of the patients without a second causal CNV may 
uncover coding mutations that would contribute to the developmental burden of ELP4 loss. 
 
The predominance in our datasets of deletions verses duplications is unlikely to be a platform 
bias as both aCGH and SNP arrays were used. Deletion enrichment could be a consequence of 
undiagnosed duplications, but as this study was not driven by a particular diagnosis this is 
unlikely. When CNVs are generated by non-allelic homologous recombination (NAHR) 
between low-copy repeats, a deletion and reciprocal duplication are generated (Malhotra and 
Sebat, 2012).  A possibility is that the duplications could be selected against due to negative 
genetic selection, i.e. a lower viability or fecundity of carriers. However, since the breakpoints 
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for ELP4 CNVs differ between cases and there are no low-copy repeats that could explain the 
generation of CNVs, this mechanism is also unlikely. Instead, there is more in common with 
deletions seen at NRXN1, which may occur by a mechanism involving inverted repeats of 
variable sizes, or a significantly higher AT nucleotide content at the breakpoints, generating a 
rearrangement hotspot of genome instability. These non-recurrent breakpoints could be 
generated by a non-homologous end joining mechanism of double strand breaks or by 
replication errors and may be influenced by the genomic architecture of a region in particular 
people, (Enggaard Hoeffding, et al., 2014).  
 
Examination of the data from the copy number variation morbidity map of developmental 
delay (Cooper, et al., 2011) shows four microdeletions (<1Mb) with breakpoints within ELP4 
(n=15,767), and five microduplications, Supplementary Information Table 1. All duplication 
cases had neurological deficits, and two deletion cases and one duplication had ASD.  
However, seven microdeletions of ELP4 were also found in the 8,329 control individuals, one 
of which is the WTCCC sample reported here. This increase in frequency of smaller CNVs 
among controls compared to all of the other control datasets used in our study, indicates that 
they may be due to an artifact from the less dense Illumina arrays used by Cooper et al, 
compared to the more rigorous platform and methods used to analyse their cases. Indeed, the 
authors commented that their detection power is substantially higher for cases, the reverse of 
our study, and will manifest itself as false positive enrichment for CNVs in controls. 
However, more information (not publicly available) is needed about the specific arrays used 
for each control with an ELP4 deletion, their LRR and BAF images and probe coverage over 
ELP4 to draw further conclusions about potential false positives and array bias in their 
investigation. 
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Future work will focus on the functional consequences of the ELP4 deletions by investigation 
of expression levels of the gene in these cases. Work with cellular and animal models with 
ELP4 deletions will help to cement the role of ELP4 in neurodevelopment through 
identification of altered interaction networks and developmental pathways such as neuronal 
migration, branching and survival. 
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FIGURE LEGEND 
 
Figure 1 Deletions (red) and a duplication (blue) identified over the ELP4-PAX6 locus on 
11p13 in 9 patients from the BB-GRE clinical genetic database with neurodevelopmental 
phenotypes, 6 patients with autism from the AGP and Canadian ASD resource, and 9 patients 
with neurodevelopmental phenotypes from the DECIPHER database. Hg19 
(http://genome.ucsc.edu/). Tracks showing positions of probes genotyped from the Illumina 
1M Single Array, the Affymetrix GenomeWide Human SNP6 Array and the Custom Agilent 
oligonucleotide array used for BBGRE patients are above the UCSC gene tracks. 
Alternatively spliced gene transcripts are shown. 
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Table 1.  Microdeletions and a microduplication of ELP4 on Chr11 identified in 9 patients from the BB-GRE clinical genetic database, 
(http://bbgre-dev.iop.kcl.ac.uk).  AgeAtTest indicates age at arrayCGH testing. 
ID Sex AgeAtTest Phenotype hg19Start hg19Stop Size bp Inheritance CNV Other CNV 
129016 F 3 years 
Developmental delay 
(progressing), microcephaly, 
poor balance 31,573,422 31,674,789 101,368 Unknown X1  
119460 M 2 years 
Social communication 
difficulties, speech and 
language delay 31,561,220 31,625,448 64,229 Maternal x1 
Deletion 
Chr5:97,302,377-
97,380,022. No 
genes. 
116589 M 3 years 
PDD: Social interaction 
difficulties, language disorder, 
behaviour problems. 31,584,329 31,642,325 57,997 Maternal x1  
108970 M 5 years 
Severe cognitive delay (IQ 20-
34) speech & language disorder, 
reading & spelling development 
disorder, autism spectrum 
disorder, epilepsy >24 months 
at age of onset 31,495,260 31,546,276 51,017 Paternal x1  
117374 M 20 years 
 
Autism, learning difficulties 31,705,076 31,747,631 42,556 Maternal x1  
112601 F 1 year 
Developmental delay, speech & 
language disorder, 
microcephaly (<5th centile), 
mild cognitive delay, motor 
skills development disorder 31,691,270 31,722,740 31,471 Paternal x1 
Duplication 
Chr5: 
93,197,999-
93,424,468. 
Disrupts 
FAM172A. 
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117003 M 8 months 
Developmental delay, 
hypotonia, ventriculomegaly 31,601,768 31,632,347 30,580 Maternal x1  
130693 M 5 years 
Moderate developmental delay 
mainly affecting language, 
emerging autistic traits 31,760,904 31,786,914 26,010 De novo x1 
Deletion Chr6: 
26,440,746-
26,463,502. 
Disrupts BTN3A3 
and BTN2A1. 
112031 F 12 years 
Developmental delay, 
hypotonia 31,616,889 31,849,574 232,686 Unknown x3 
Deletion Chr16: 
15,048,750-
16,305,736 
16p13.11 
hotspot. 
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Table 2.  Microdeletions of ELP4 on Chr11 identified in 9 individuals from the DECIPHER database. Age indicates age at last clinical 
assessment. 
ID Sex Age Phenotype hg19Start hg19Stop Size bp Inheritance CNV Other CNV 
265704 M <1yr 
Aniridia. No further 
information. 31,172,410 31,775,457 603,047 De novo x1 
 
249728 F 24yrs Rieger anomaly.  31,118,027 31,710,576 592,549 De novo x1 
 
257614 M 7yrs 
Epilepsy – partial complex 
seizures with secondary 
generalization due to cortical 
dysplasia, mild developmental 
delay, ADHD, neurinomas, 
congenital malformation in left 
eye, fine motor dyspraxia. 30,991,456 31,564,708 573,252 Parent x1 
 
292869 F 15yrs 
Severe  intellectual disability, 
muscle hypotrophy with severe 
hypotonia and absent gross 
motor and fine adaptive motor 
development; no language; 
severe dysphagia requiring tube 
feeding; craniofacial 
abnormalities. 31,597,322 31,802,120 204,798 De novo x1 
 
287341 M 2yrs 
Partial aniridia. Currently no 
signs of neurological 
impairment. 31,605,859 31,783,590 177,731 Maternal x1 
 
258970 M 4 yrs 
Developmental delay, 
behavioral disturbances, 
regression of language at 18mo 
to absent at age 4, pervasive 
developmental disorder 31,605,859 31,775,457 169,598 Unknown x1 
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261471 M 4yrs 
Behavioral and speech 
disorders, mild mental 
retardation. 31,625,389 31,775,457 150,068 Parent x1 
Deletion 
Chr10:35360169-
35605506 
disrupting CUL2, 
CREM, CCNY. 
289275 M 24yrs 
Aniridia, global developmental 
delay, autistic behaviour.  31,742,075 31,870,603 128,528 Unknown x1 
Duplication 
ChrX:46389227-
46396390 
disrupting intron 
of ZNF674. 
270752 F 9yrs 
Aniridia, congenital cataract. 
Mild developmental delay due 
to processing speed deficiencies 
largely due to visual 
impairment. 31,735,689 31,825,698 90,009 Paternal x1 
 
Page 32 of 33
John Wiley & Sons, Inc.
Human Mutation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Table 3.  Microdeletions of ELP4 on Chr11 identified in 3 patients from the Autism Genome Project and 3 from a Canadian study of 
autism. * sibling sister pair. 
Autism Study ID Sex Phenotype hg19Start hg19Stop Size bp Inheritance CNV Other CNV 
3617_3 M 
Strict autism; no seizures, verbal, 
language delay; delayed first 
words (at 24 mo), delayed first 
phrases (at 36 mo); verbal IQ 
>70. 31460506 31655108 194,602 Paternal x1 
 
NA0285 M 
Autism, language delay; delayed 
first words (at 32 mo), no seizures 31518924 31649475 130,551 Maternal x1 
 
8596_201 M 
Strict autism, high functioning; no 
seizures, verbal, language delay; 
delayed first words (at 25 mo), 
typical first phrases (at 25 mo); 
verbal IQ >70. 31488890 31607986 119,096 Maternal x1 
Duplication, 
chr9:115994263-
116495631 
disrupting COL27A1 
MM1259-003* F 
Autism, language delay; delayed 
first words (at 21 mo), mild 
developmental delay, motor 
delay, no seizures 31652219 31764393 112,174 Unknown x1 
Deletion 
chrX:154772341-
154775951 
disrupting TMHLE 
MM1259-004* F 
Autism, language delay; delayed 
first words (at 18 mo), delayed 
first phrases (at 36 mo), 
expressive language problems, 
mild developmental delay, motor 
delay, no seizures 31652219 31764393 112,174 Unknown x1 
Deletion 
chrX:154772341-
154775951 
disrupting TMHLE 
20130_6005001 M 
Strict autism; no seizures, verbal, 
language delay; delayed first 
words (at 36 mo), delayed first 
phrases (at 48 mo); verbal IQ 
>70, coordination problems 31576768 31653568 76,800 Maternal x1 
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Supplementary Table 1 Microdeletions and duplications disrupting ELP4 reported in cases and controls from the copy number variation 
morbidity map of developmental delay (Cooper et al., 2011). 
  
Sample ID Variant ID hg19Start hg19Stop Size bp CNV 
Cases:      
9890931 nsv540979 31,118,026 31,790,388 672,363 x3 
9882508 nsv540980 31,152,003 31,751,699 599,697 x1 
9896715 nsv540981 31,401,095 31,656,511 255,417 x1 
9908285 nsv540986 31,747,371 32,063,394 315,979 x3 
9883063 nsv540987 31,775,599 31,804,354 28,756 x1 
9882119 nsv540982 31,602,061 31,875,238 273,178 x3 
9899815 nsv540983 31,656,450 31,857,797 201,348 x3 
9883029 nsv540984 31,703,100 31,751,699 48,600 x1 
9889844 nsv540985 31,703,100 31,929,503 226,404 x3 
Controls:      
WTCCC nsv553949 31,317,835 31,539,587 221,753 x1 
 nsv553989 31,727,232 31,796,560 69,329 x1 
HGDP00106 nsv5553987 31,488,890 31,696,336 207,447 x1 
 nsv553986 31,488,890 31,679,048 190,159 x1 
 nsv553988 31,535,355 31,651,189 115,835 x1 
 nsv553984 31,454,975 31,654,406 199,432 x1 
 nsv553985 31,488,890 31,654,406 165,517 x1 
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